These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38333688)

  • 21. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
    Callander NS; Silbermann R; Kaufman JL; Godby KN; Laubach J; Schmidt TM; Sborov DW; Medvedova E; Reeves B; Dhakal B; Rodriguez C; Chhabra S; Chari A; Bal S; Anderson LD; Dholaria BR; Nathwani N; Hari P; Shah N; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Pei H; Cortoos A; Patel S; Lin TS; Giri S; Costa LJ; Usmani SZ; Richardson PG; Voorhees PM
    Blood Cancer J; 2024 Apr; 14(1):69. PubMed ID: 38649340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment.
    Saeed N; Khan Z; Jehanzeb H; Shaikh T; Shaikh U; Adil SN; Madni V; Fatima H; Abiha UE; Ali N
    Cureus; 2024 Apr; 16(4):e58999. PubMed ID: 38800157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials.
    Sekine L; Ziegelmann PK; Manica D; Pithan CDF; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
    Crit Rev Oncol Hematol; 2019 Nov; 143():102-116. PubMed ID: 31563077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma.
    Fonseca R; Facon T; Hashim M; Nair S; He J; Ammann E; Lam A; Wildgust M; Kumar S
    Oncologist; 2023 May; 28(5):e263-e269. PubMed ID: 37002943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
    Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
    Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
    Sborov DW; Baljevic M; Reeves B; Laubach J; Efebera YA; Rodriguez C; Costa LJ; Chari A; Silbermann R; Holstein SA; Anderson LD; Kaufman JL; Shah N; Pei H; Patel S; Cortoos A; Bartlett JB; Vermeulen J; Lin TS; Voorhees PM; Richardson PG
    Br J Haematol; 2022 Nov; 199(3):355-365. PubMed ID: 36111391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
    Okazuka K; Ishida T; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Tsukada N; Suzuki K
    Eur J Haematol; 2020 Feb; 104(2):110-115. PubMed ID: 31733155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
    Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Béné MC; Zweegman S; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Stoppa AM; van de Donk NWCJ; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Krevvata M; Zhang K; de Boer C; Vara S; Kampfenkel T; Vanquickelberghe V; Vermeulen J; Avet-Loiseau H; Sonneveld P
    Lancet Oncol; 2021 Oct; 22(10):1378-1390. PubMed ID: 34529931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
    Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
    JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
    O'Donnell EK; Laubach JP; Yee AJ; Chen T; Huff CA; Basile FG; Wade PM; Paba-Prada CE; Ghobrial IM; Schlossman RL; Burke JN; Harrington CC; Lively KJ; Lyons HF; Munshi NC; Anderson KC; Trippa L; Richardson PG; Raje NS
    Br J Haematol; 2018 Jul; 182(2):222-230. PubMed ID: 29740809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN.
    Voorhees PM; Rodriguez C; Reeves B; Nathwani N; Costa LJ; Lutska Y; Bobba P; Hoehn D; Pei H; Ukropec J; Qi M; Lin TS; Richardson PG
    Blood Adv; 2021 Feb; 5(4):1092-1096. PubMed ID: 33606004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis.
    Xu W; Li D; Sun Y; Ran X; Wang B; Wu W; Sheng Z; Liu L
    Eur J Haematol; 2019 Dec; 103(6):542-551. PubMed ID: 31444819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.
    Yimer H; Melear J; Faber E; Bensinger WI; Burke JM; Narang M; Stevens D; Gray KS; Lutska Y; Bobba P; Qi K; Hoehn D; Qi M; Lin TS; Rifkin RM
    Leuk Lymphoma; 2022 Oct; 63(10):2383-2392. PubMed ID: 35730586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study.
    Takamatsu H; Iida S; Shibayama H; Shibayama K; Yamazaki H; Suzuki K
    Int J Hematol; 2020 May; 111(5):692-701. PubMed ID: 32002821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients.
    Zhou Q; Xu F; Wen J; Yue J; Zhang Y; Su J; Liu Y
    Clin Exp Med; 2023 Sep; 23(5):1573-1580. PubMed ID: 36094683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma.
    Durie BGM; Kumar SK; Usmani SZ; Nonyane BAS; Ammann EM; Lam A; Kobos R; Maiese EM; Facon T
    Am J Hematol; 2020 Dec; 95(12):1486-1494. PubMed ID: 32804408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
    Lee JY; Park SS; Jeon YW; Shin SH; Yahng SA; Min CK;
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11907-11918. PubMed ID: 37418057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
    Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK
    J Clin Oncol; 2020 Jun; 38(17):1928-1937. PubMed ID: 32298201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.